SEGMENTS (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Facility	Dec. 31, 2021 USD ($)
Segment Reporting Information [Abstract]
Number of plasma collection facilities under development | Facility	10
Number of operational collection plasma facilities | Facility	9
Number of FDA-licensed plasma collection facilities | Facility	7
Number of FDA-licensed plasma collection facilities received approval from Korean Ministry of Food and Drug Safety | Facility	3
Revenues	$ 154,079,692	$ 80,942,625
Cost of product revenue	118,814,535	79,769,341
Income (loss) from operations	(39,365,080)	(58,373,741)
Interest and other expense, net	(19,868,929)	(13,273,877)
Loss on extinguishment of debt	(6,669,941)	0
Net income (loss)	(65,903,950)	(71,647,618)
Capital expenditures	13,911,171	13,511,258
Depreciation and amortization expense	7,113,369	5,495,502
Total assets	348,461,881	276,252,724
Corporate [Member]
Segment Reporting Information [Abstract]
Revenues	142,834	142,834
Cost of product revenue	0	0
Income (loss) from operations	(22,336,089)	(17,024,068)
Interest and other expense, net	(19,360,876)	(13,050,164)
Loss on extinguishment of debt	(6,669,941)
Net income (loss)	(48,366,906)	(30,074,232)
Capital expenditures	0	0
Depreciation and amortization expense	918	5,334
Total assets	73,231,812	43,180,014
Operating Segments [Member] | ADMA BioManufacturing [Member]
Segment Reporting Information [Abstract]
Revenues	144,069,543	74,935,528
Cost of product revenue	108,881,938	74,124,999
Income (loss) from operations	879,387	(29,293,309)
Interest and other expense, net	(504,787)	(218,053)
Loss on extinguishment of debt	0
Net income (loss)	374,600	(29,511,362)
Capital expenditures	5,246,860	4,876,983
Depreciation and amortization expense	4,708,879	4,217,771
Total assets	238,159,534	208,391,019
Operating Segments [Member] | Plasma Collection Centers [Member]
Segment Reporting Information [Abstract]
Revenues	9,867,315	5,864,263
Cost of product revenue	9,932,597	5,644,342
Income (loss) from operations	(17,908,378)	(12,056,364)
Interest and other expense, net	(3,266)	(5,660)
Loss on extinguishment of debt	0
Net income (loss)	(17,911,644)	(12,062,024)
Capital expenditures	8,664,311	8,634,275
Depreciation and amortization expense	2,403,572	1,272,397
Total assets	$ 37,070,535	$ 24,681,691